TWI891608B - 用於治療腎臟病之化合物 - Google Patents
用於治療腎臟病之化合物Info
- Publication number
- TWI891608B TWI891608B TW108126640A TW108126640A TWI891608B TW I891608 B TWI891608 B TW I891608B TW 108126640 A TW108126640 A TW 108126640A TW 108126640 A TW108126640 A TW 108126640A TW I891608 B TWI891608 B TW I891608B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- cpd
- pharmaceutically acceptable
- compounds
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18185871 | 2018-07-26 | ||
| EP18185871.3 | 2018-07-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202019486A TW202019486A (zh) | 2020-06-01 |
| TWI891608B true TWI891608B (zh) | 2025-08-01 |
Family
ID=63077813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108126640A TWI891608B (zh) | 2018-07-26 | 2019-07-26 | 用於治療腎臟病之化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20200085810A1 (https=) |
| EP (2) | EP3826679B1 (https=) |
| JP (2) | JP7478133B2 (https=) |
| KR (1) | KR102860768B1 (https=) |
| CN (2) | CN112469442B (https=) |
| AU (1) | AU2019310919B2 (https=) |
| CA (1) | CA3104793A1 (https=) |
| ES (1) | ES3005632T3 (https=) |
| IL (1) | IL280368B2 (https=) |
| MX (1) | MX2021000976A (https=) |
| PL (1) | PL3826679T3 (https=) |
| TW (1) | TWI891608B (https=) |
| WO (1) | WO2020021097A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200085810A1 (en) * | 2018-07-26 | 2020-03-19 | Hoffmann-La Roche Inc. | Compounds for use in treating kidney disorders |
| WO2022006277A1 (en) * | 2020-07-01 | 2022-01-06 | Angion Biomedica Corp. | Methods for treatment of fibrotic kidney diseases |
| US11814354B2 (en) * | 2021-09-08 | 2023-11-14 | River 3 Renal Corp. | Solid forms |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1270846B (it) | 1993-05-10 | 1997-05-13 | Alfa Wassermann Spa | Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della nefropatia diabetica. |
| US7030146B2 (en) | 1996-09-10 | 2006-04-18 | University Of South Carolina | Methods for treating diabetic neuropathy |
| PT1732892E (pt) | 2004-03-26 | 2008-12-22 | Hoffmann La Roche | Tetra-hidrocarbazóis e os seus derivados |
| JP4682192B2 (ja) | 2004-05-03 | 2011-05-11 | エフ．ホフマン−ラ ロシュ アーゲー | 肝ｘ受容体モジュレータとしてのインドリル誘導体 |
| UA107088C2 (xx) | 2009-09-11 | 2014-11-25 | 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину | |
| AR079022A1 (es) * | 2009-11-02 | 2011-12-21 | Sanofi Aventis | Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion |
| WO2012031817A1 (en) * | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
| AR085013A1 (es) * | 2011-01-26 | 2013-08-07 | Sanofi Aventis | Derivados de acido 3-heteroaroilamino-propionico sustituidos y su uso como sustancias farmaceuticas |
| US9321727B2 (en) * | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| KR20140057652A (ko) * | 2011-09-12 | 2014-05-13 | 에프. 호프만-라 로슈 아게 | Hdl-콜레스테롤 상승제로서의 3-피리딘 카복실산 하이드라자이드 |
| WO2014180741A1 (en) * | 2013-05-06 | 2014-11-13 | F. Hoffmann-La Roche Ag | Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7 |
| KR20160030206A (ko) | 2013-07-10 | 2016-03-16 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 사구체 질환을 치료하는데 사용하기 위한 로스마피모드 |
| US20200085810A1 (en) * | 2018-07-26 | 2020-03-19 | Hoffmann-La Roche Inc. | Compounds for use in treating kidney disorders |
-
2019
- 2019-07-25 US US16/522,116 patent/US20200085810A1/en not_active Abandoned
- 2019-07-26 CN CN201980048869.4A patent/CN112469442B/zh active Active
- 2019-07-26 EP EP19749657.3A patent/EP3826679B1/en active Active
- 2019-07-26 AU AU2019310919A patent/AU2019310919B2/en active Active
- 2019-07-26 PL PL19749657.3T patent/PL3826679T3/pl unknown
- 2019-07-26 KR KR1020217002388A patent/KR102860768B1/ko active Active
- 2019-07-26 CN CN202311697211.0A patent/CN117736141A/zh active Pending
- 2019-07-26 TW TW108126640A patent/TWI891608B/zh active
- 2019-07-26 JP JP2021504186A patent/JP7478133B2/ja active Active
- 2019-07-26 IL IL280368A patent/IL280368B2/en unknown
- 2019-07-26 ES ES19749657T patent/ES3005632T3/es active Active
- 2019-07-26 EP EP24213767.7A patent/EP4537901A3/en active Pending
- 2019-07-26 WO PCT/EP2019/070251 patent/WO2020021097A1/en not_active Ceased
- 2019-07-26 MX MX2021000976A patent/MX2021000976A/es unknown
- 2019-07-26 CA CA3104793A patent/CA3104793A1/en active Pending
-
2021
- 2021-03-19 US US17/206,955 patent/US20210275514A1/en not_active Abandoned
-
2024
- 2024-03-27 US US18/618,124 patent/US20240325372A1/en active Pending
- 2024-04-19 JP JP2024068208A patent/JP2024096989A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3826679A1 (en) | 2021-06-02 |
| CN112469442B (zh) | 2024-04-09 |
| EP4537901A2 (en) | 2025-04-16 |
| US20200085810A1 (en) | 2020-03-19 |
| KR20210038884A (ko) | 2021-04-08 |
| EP3826679B1 (en) | 2024-11-27 |
| KR102860768B1 (ko) | 2025-09-17 |
| CN112469442A (zh) | 2021-03-09 |
| IL280368B1 (en) | 2023-10-01 |
| CN117736141A (zh) | 2024-03-22 |
| AU2019310919A1 (en) | 2021-01-07 |
| WO2020021097A1 (en) | 2020-01-30 |
| MX2021000976A (es) | 2021-03-31 |
| ES3005632T3 (en) | 2025-03-14 |
| US20240325372A1 (en) | 2024-10-03 |
| AU2019310919B2 (en) | 2025-04-03 |
| IL280368A (en) | 2021-03-25 |
| US20210275514A1 (en) | 2021-09-09 |
| JP7478133B2 (ja) | 2024-05-02 |
| EP3826679C0 (en) | 2024-11-27 |
| PL3826679T3 (pl) | 2025-03-10 |
| EP4537901A3 (en) | 2025-05-21 |
| IL280368B2 (en) | 2024-02-01 |
| JP2021531308A (ja) | 2021-11-18 |
| TW202019486A (zh) | 2020-06-01 |
| JP2024096989A (ja) | 2024-07-17 |
| CA3104793A1 (en) | 2020-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240325372A1 (en) | Compounds for use in treating kidney disorders | |
| KR101509829B1 (ko) | 혈소판 ａｄｐ 수용체 억제제로 작용하는 화합물을 이용한 병용요법 | |
| JP2019526582A (ja) | 縮合二環式ｓｇｃ刺激剤 | |
| JP2021535126A (ja) | Ｎａｓｈ／ｎａｆｌｄおよび関連疾患の治療のための組合せ | |
| EP3411026B1 (en) | Use of stimulators of soluble guanylate cyclase for the treatment of nonalcoholic steatohepatitis (nash) | |
| SG176477A1 (en) | Indole compounds | |
| JP2016540017A (ja) | ｓＧＣ刺激物質 | |
| TW200401768A (en) | Methods of treatment with CETP inhibitors and antihypertensive agents | |
| JP2017527605A (ja) | ｓＧＣ刺激剤 | |
| US20250066337A1 (en) | Amorphous Form of (S)-2-(5-((3-Ethoxypyridin-2-YL)Oxy)Pyridin-3-YL)-N-(Tetrahydrofuran-3-YL)Pyrimidine-5-Carboxamide | |
| CN113924295A (zh) | 激酶抑制剂 | |
| JP2022062115A (ja) | ｓＧＣ刺激剤のリンプロドラッグ | |
| KR20200054910A (ko) | 젬카빈, 이의 약학적으로 허용 가능한 염, 조성물 및 이의 사용 방법 | |
| WO2023023867A1 (en) | Compounds for reducing cholesterol and treating liver and kidney disease | |
| HK40102350A (zh) | 用於治疗肾脏疾患的化合物 | |
| HK40040900B (zh) | 用於治疗肾脏疾患的化合物 | |
| HK40040900A (en) | Compounds for use in treating kidney disorders | |
| HK40001613B (en) | Use of stimulators of soluble guanylate cyclase for the treatment of nonalcoholic steatohepatitis (nash) | |
| HK1136563A (en) | Indole compounds |